Fundraising Fox

Fore

Philadelphia, US · 55 employees on LinkedIn · 7 known investors

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program. It runs clinical trials such as the Forte Trial and offers expanded access programs for patients.

BiotechHealthtechMedical Devices

Investors · 7

LG Technology VenturesSanta Clara
Novartis Venture FundBasel · $5M – $25M
OrbiMedNew York · $1M – $75M
Pontifax Venture CapitalHerzeliya · $6.3M – $128M
Windham Capital PartnersNew York · $1M – $5M
MedicxireportedLondon
SymBiosisreportedBentonville

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries D-2 ExtensionJul 2026
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 1

by search overlap
Fortress Biotech29 shared keywordsFortress Biotech is a biopharmaceutical company that develops and commercializes pharmaceutical products, maintaining a pipeline of both revenue-generating commercial-stage products and development-stage drug candidates. It advances its products through partnerships within the pharmaceutical industry.

Companies competing with Fore for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Fore Biotherapeutics lands $67M extension to support ongoing cancer drug developmenttechnical.ly · Aug 2026FORE Biotherapeutics Raises $67.4M in Series D-2 Extension Fundingfinsmes.com · Jul 2026Fore Biotherapeutics secures $67M in one of year's largest biotech funding rounds - Philadelphia Business Journalbizjournals.com · Jul 2026The Fore’s Funding Programme Opens for Registration on 25 March — Supporting Communitiessupportingcommunities.org · Mar 2026Apply for funding - The Forethefore.org · Feb 2023Who we fund - The Forethefore.org · Oct 2019

Frequently asked questions

What does Fore do?
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program. It runs clinical trials such as the Forte Trial and offers expanded access programs for patients.
Who are Fore's investors?
Fore's investors include LG Technology Ventures, Novartis Venture Fund, OrbiMed, Pontifax Venture Capital, Windham Capital Partners, Medicxi, SymBiosis.
Where is Fore headquartered?
Fore is headquartered in Philadelphia, US.